SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

June 17, 2010 08:30 ET

Cleveland BioLabs Chief Scientific Officer to Speak at Prestigious St. Petersburg International Economic Forum

BUFFALO, NY--(Marketwire - June 17, 2010) -  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that Andrei Gudkov, Ph.D., D. Sci., the Company's Chief Scientific Officer and Senior Vice President of Basic Science at Roswell Park Cancer Institute, is scheduled to speak at the St. Petersburg International Economic Forum (SPIEF), June 17-19, in St. Petersburg, Russian Federation.

Dr. Gudkov will participate in a panel session on June 19, titled, "Russia and the 'Global' Russians," which is intended to explore what needs to be done to make use of the potential of "Global" Russians around the world for the purpose of modernizing Russian society and the economy.

"It is an honor to be invited to participate in such a prestigious forum, which brings together creative minds from all over the world," stated Dr. Gudkov. "I hope to share my own experiences as a Russian-born scientist and entrepreneur living abroad who has been able to leverage knowledge of both societies to effectively establish collaborative initiatives. I believe that the recent launch of Incuron, a joint Russian-US venture funded by Bioprocess Capital Ventures, LLC, a Russian Federation venture capital fund, is an excellent example of this strategy and the ability of 'global' Russians to bring expertise back to benefit the people of their country of origin."

The St. Petersburg International Economic Forum is held annually with the support and participation of the President of the Russian Federation. The Forum gathers the world's leading decision makers from government, business and civil society to identify and deliberate the key challenges facing emerging markets and the world and engage communities to find common purpose and frameworks to forge solutions.

For more information about the St. Petersburg International Economic Forum, please go to: http://www.forumspb.com/mains/eng/.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2009.

Contact Information

  • Contact:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439
    E: rlevine@cbiolabs.com